Fate Therapeutics
FATE
$3.80
Share price
-1.81%
Change (1 day)
-37.40%
Change (1 year)
Categories
Fate Therapeutics (FATE) - Total liabilities
Total liabilities on the balance sheet as of December 2023 : $0.13 B
According to Fate Therapeutics 's latest financial reports the company's total liabilities are $0.13 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Fate Therapeutics - Total liabilities on balance sheet (from 2012 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2023-12-31 | $0.13 B | -37.82% |
| 2022-12-31 | $0.22 B | -8.65% |
| 2021-12-31 | $0.24 B | 1.93% |
| 2020-12-31 | $0.23 B | 313.8% |
| 2019-12-31 | $57.51 M | 9.43% |
| 2018-12-31 | $52.56 M | 87.04% |
| 2017-12-31 | $28.1 M | 28.36% |
| 2016-12-31 | $21.89 M | -26.82% |
| 2015-12-31 | $29.92 M | 30.98% |
| 2014-12-31 | $22.84 M | 382.43% |
| 2013-12-31 | $4.73 M | -92.59% |
| 2012-12-31 | $63.9 M | 9.17% |
| 2011-12-31 | $58.53 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Becton Dickinson BDX | $26.94 B | 19,450.80% | 🇺🇸 USA |
 Sarepta Therapeutics
SRPT | $2.40 B | 1,645.46% | 🇺🇸 USA |
 PTC Therapeutics
PTCT | $2.71 B | 1,869.70% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | $1.01 B | 639.77% | 🇺🇸 USA |
 Avidity Biosciences RNA | $0.12 B | -7.26% | 🇺🇸 USA |